How cheap, fast investigator-initiated trials are upending drug development

Traditional clinical studies can move slowly. But in China, some small companies are using investigator-initiated trials, or IITs, to sidestep the process and get quick assessments of their experimental medicines. And Western companies are starting to catch on. How is the strategy affecting the typical drug development process?

sponsored by

Why clinical trials stay costly in the US – and cheap in China

Testing new drugs is expensive in the United States, and the costs keep going up. But in China, trials are much cheaper — which is one major factor contributing to the Chinese biotech boom. We’ll unpack the reasons for the discrepancy and it’s implications for the industry worldwide.

sponsored by

Merging real-world data with patient insights in kidney disease

sponsored by